All sponsors

Hutchmed $HCM

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS11
PHASE 3 / 2-38
RECRUITING8
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO57%

Delay Index: of 7 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +9.0 months). See all sponsors →

Open Hutchmed on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
wAIHA
NCT05535933
P2/3Active, not recruitingWarm Antibody Autoimmune Hemolytic Anemia1112025-11-25 (-9 mo)
HMPL-760
NCT07409428
P3RecruitingRelapsed/Refractory Diffuse Large B-Cell Lymphoma2402028-04-30
SANOVO
NCT05009836
P3Active, not recruitingNon-small Cell Lung Cancer4122028-05-30 (+42 mo)
Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine
NCT06361888
P2/3RecruitingMetastatic Pancreatic Cancer5022028-05-31 (+9 mo)
HMPL-453
NCT04353375
P2/3RecruitingAdvanced Intrahepatic Cholangiocarcinoma; Solid Tumor, Adult2352028-06-30 (+66 mo)
HMPL-A251
NCT07228247
P1/2RecruitingSolid Tumors, Adult1472028-11-30
HMPL-A580
NCT07396584
P1/2RecruitingSolid Tumors, Adult1862028-12-31
HMPL-306 Regimen
NCT06387069
P3RecruitingAcute Myeloid Leukemia3162028-12-31 (+19 mo)
fruquintinib
NCT06584032
P3RecruitingAdvanced Endometrial Cancer4122029-01-08
HMPL-A830
NCT07718581
P1/2RecruitingSolid Tumor, Adult1472029-05-23
HMPL-306 tablet
NCT07912398
P3Not yet recruitingGrade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation2102032-03